Weak µ-opioid agonist via CYP2D6-mediated conversion to O-desmethyltramadol (active metabolite with 200× µ-affinity vs parent). Parent compound is a serotonin + norepinephrine reuptake inhibitor — serotonergic load creates seizure + serotonin-syndrome risk. CYP2D6 polymorphism drives analgesia + respiratory depression variability.